Secondary prevention of stroke with antiplatelet drugs

被引:0
|
作者
Diener, HC [1 ]
机构
[1] Univ Essen Gesamthsch Klinikum, Neurol Klin, D-45147 Essen, Germany
关键词
TIA; stroke; aspirin; clopidogrel; dipyridamole;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients suffering from a transient ischemic attack (TIA) or ischemic stroke are at high risk of a recurrent stroke. The risk is between 10% and 15% in the 1st year after the event and highest in the immediate period following the index event. In patients without cardiac source of embolism, the risk of stroke can be reduced by acetylsalicylic acid (ASA). The relative risk reduction for recurrent vascular events (myocardial infarction, stroke, vascular death) with aspirin is 18% and the risk reduction for stroke 13%. Clopidogrel is superior to ASA in patients with high risk of recurrence due to concomitant vascular disease or multiple risk factors. Clinical trials for secondary stroke prevention at present focus on combination antiplatelet therapy. Large clinical trials such as MATCH, CARESS, CHARISMA, and PKoFESS will investigate whether combination antiplatelet therapy is superior to monotherapy and whether the combination of dipyridamole plus ASA is comparable to clopidogrel plus ASA in terms of efficacy and safety.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 50 条
  • [11] Antiplatelet Therapy in the Secondary Prevention of Stroke
    Graeme J. Hankey
    中国循证医学杂志, 2004, (03) : 150 - 156
  • [12] Antiplatelet Drugs for Ischemic Stroke Prevention
    Leys, Didier
    Balucani, Clotilde
    Cordonnier, Charlotte
    CEREBROVASCULAR DISEASES, 2009, 27 : 120 - 125
  • [13] Antiplatelet agents for secondary prevention of stroke
    Bernstein R.A.
    Current Treatment Options in Cardiovascular Medicine, 2008, 10 (3) : 223 - 228
  • [14] Antiplatelet treatment in primary and secondary stroke prevention in women
    Caso, Valeria
    Santalucia, Paola
    Acciarresi, Monica
    Pezzella, Francesca Romana
    Paciaroni, Maurizio
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2012, 23 (07) : 580 - 585
  • [15] Selecting an Optimal Antiplatelet Agent for Secondary Stroke Prevention
    Albright, Karen C.
    Howard, Virginia J.
    Howard, George
    NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (02) : E121 - E128
  • [16] Aspirin and Antiplatelet Agent ResistanceImplications for Prevention of Secondary Stroke
    David M. Greer
    CNS Drugs, 2010, 24 : 1027 - 1040
  • [17] Secondary Stroke Prevention with Antithrombotic Drugs
    De Schryver, Els Lisette Leo Maria
    Algra, Ale
    CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (01) : 129 - 133
  • [18] Current Guidelines on Antiplatelet Agents for Secondary Prevention of Noncardiogenic Stroke: An Evidence-Based Review
    Simmons, B. Brent
    Yeo, Albert
    Fung, Kent
    POSTGRADUATE MEDICINE, 2010, 122 (02) : 49 - 53
  • [19] Drugs in secondary stroke prevention
    Tremonti, Chris
    Thieben, Mark
    AUSTRALIAN PRESCRIBER, 2021, 44 (03) : 85 - 90
  • [20] Clinical Pharmacokinetics of Antiplatelet Agents Used in the Secondary Prevention of Stroke
    Thomas L. Lenz
    Amy F. Wilson
    Clinical Pharmacokinetics, 2003, 42 : 909 - 920